Sara Bonstein Sells 18,322 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 18,322 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at $9,545,887.53. This represents a 13.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, February 11th, Sara Bonstein sold 13,302 shares of Insmed stock. The stock was sold at an average price of $80.00, for a total transaction of $1,064,160.00.
• On Thursday, February 6th, Sara Bonstein sold 28,390 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $2,296,751.00.
• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Stock Down 0.3 %

Shares of Insmed stock traded down $0.22 during trading on Thursday, hitting $83.61. 2,291,313 shares of the stock traded hands, compared to its average volume of 1,925,492. The firm has a market cap of $14.96 billion, a P/E ratio of -15.06 and a beta of 1.11. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.28. The stock’s fifty day simple moving average is $73.87 and its 200 day simple moving average is $73.45.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). On average, equities analysts predict that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Darwin Global Management Ltd. grew its stake in Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Insmed by 1.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock valued at $877,113,000 after purchasing an additional 123,429 shares during the last quarter. Capital International Investors grew its stake in Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock valued at $491,357,000 after purchasing an additional 593,206 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Insmed by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock valued at $282,243,000 after purchasing an additional 273,759 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Truist Financial reaffirmed a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday. Wells Fargo & Company increased their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Stifel Nicolaus increased their price objective on shares of Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $90.86.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.